MDM4 and Merkel cell skin cancer: When added to HDM201 treatment, a selective MDM2 inhibitor, Lenalidomide, substantially enhanced its efficacy in MKL-1 MCC xenografts, which allows us to hypothesize that a combination of MDM4 and MDM2 inhibition could be beneficial in MCC [65].